Literature DB >> 10102765

Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results.

K E Hutchison1, P M Monti, D J Rohsenow, R M Swift, S M Colby, M Gnys, R S Niaura, A D Sirota.   

Abstract

Although several studies have examined the effects of opioid antagonists on smoking behavior, there have been no reports of the potentially therapeutic combination of naltrexone and nicotine replacement therapy. The primary objective of the present study was to determine whether naltrexone reduced reactivity to smoking cues among abstinent smokers treated with nicotine replacement. Twenty participants were instructed to abstain from smoking cigarettes for 9 h while using nicotine replacement therapy. Participants were subsequently treated with either naltrexone (50 mg) or placebo before being exposed to smoking cues. Results indicated that the smokers who received the placebo responded to smoking cue exposure with increases in urge to smoke and increases in negative affect. Participants who received naltrexone did not show any increase in urge or negative affect and showed a decrease in withdrawal symptoms after exposure to smoking cues. Although preliminary, the findings suggest that naltrexone may work in combination with nicotine replacement therapies to block the effects of smoking stimuli in abstinent smokers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102765     DOI: 10.1007/s002130050872

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

Review 1.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

2.  Cue-elicited negative affect in impulsive smokers.

Authors:  Neal Doran; Jessica Cook; Dennis McChargue; Mark Myers; Bonnie Spring
Journal:  Psychol Addict Behav       Date:  2008-06

3.  Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow; Gary B Kaplan; Robert M Swift; Amy B Adolfo
Journal:  Nicotine Tob Res       Date:  2008-06       Impact factor: 4.244

4.  Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats.

Authors:  Xiu Liu; Matthew I Palmatier; Anthony R Caggiula; Alan F Sved; Eric C Donny; Maysa Gharib; Sheri Booth
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

Review 5.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

6.  Differences in Magnitude of Cue Reactivity Across Durations of Smoking History: A Meta-analysis.

Authors:  Joshua L Karelitz
Journal:  Nicotine Tob Res       Date:  2020-07-16       Impact factor: 4.244

Review 7.  Current perspectives on smoking cessation among substance abusers.

Authors:  Maria A Sullivan; Lirio S Covey
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

8.  Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

Review 9.  Developing human laboratory models of smoking lapse behavior for medication screening.

Authors:  Sherry A McKee
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

10.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.